Patent ID: 6025335
Filing Date: 2000-02-15
Classification: A61P,C07H,Y02A,Y10S

Abstract:
A compound selected from the group consisting of: ##STR3## and pharmaceutically acceptable salts thereof, wherein: B.sub.1 and B.sub.2 are each selected from the group consisting of .beta.-D, .beta.-L and .alpha.-L nucleosides and at least one of B.sub.1 or B.sub.2 must be a .beta.-L or .alpha.-L nucleoside, wherein:R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of cytosine, thymidine, uracil, adenine, guanine, inosine, 5-fluorouridine, and 5-halo substituted pyrimidine bases, and wherein when B.sub.1 or B.sub.2 is attached to the internucleotide binding agent, IBA, at the 5'-position and said B.sub.1 or B.sub.2 is .beta.-L or .alpha.-L, then the R.sub.1 or R.sub.2 attached to said base cannot be cytosine; andIBA is selected from the group consisting of phosphodiesters, phosphorothioate, methoxy phosphotriesters, methylphosphonates, phosphorodithioates, silyl ethers, sulphonates and ethylenedioxy ethers.